Compare Gilead Sciences, Inc. (GILD) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Oatly Group AB - ADR — how do they compare? Gilead Sciences, Inc. trades at $134.8 (market cap $163.51B), while Oatly Group AB - ADR trades at $10.08 (market cap $305.54M). The key difference: Gilead Sciences, Inc. is far larger — about 535.2× Oatly Group AB - ADR's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| GILD | OTLY | |
|---|---|---|
Market Cap | $163.51B | $305.54M |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $18.54 |
52-Week Low | $108.22 | $8.03 |
Enterprise Value | $178.05B | $803.15M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
OTLY trades at $9.97, up 2.15% today, with a bullish technical signal despite mixed moving averages. Revenue grew to $862M in 2025, but net losses persist at -$153M. The company maintains a strong brand presence, with recent product expansions in Canada and a partnership with Nespresso. Cash burn remains a concern, with negative operating cash flow of -$24M in 2025. Analyst consensus is divided, with 44% buy ratings but 50% hold, reflecting cautious optimism amid financial challenges.
Outlook: OTLY shows potential for growth through market expansion and cost management, but high debt and sustained losses pose significant risks. Investment appeal hinges on achieving profitability and reducing cash burn. Key catalysts include Q2 2026 earnings on July 22, 2026, and execution of strategic initiatives. Risks include liquidity constraints and competitive pressures in the plant-based beverage sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
